CS-3150
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Essential Hypertension
Conditions
Essential Hypertension
Trial Timeline
Mar 1, 2016 → Jul 8, 2017
NCT ID
NCT02722265About CS-3150
CS-3150 is a phase 3 stage product being developed by Daiichi Sankyo for Essential Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02722265. Target conditions include Essential Hypertension.
What happened to similar drugs?
15 of 20 similar drugs in Essential Hypertension were approved
Approved (15) Terminated (2) Active (5)
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02885662 | Pre-clinical | Completed |
| NCT02807974 | Phase 3 | Completed |
| NCT02808026 | Phase 3 | Completed |
| NCT02807987 | Phase 3 | Completed |
| NCT02722265 | Phase 3 | Completed |
| NCT02448628 | Phase 2 | Completed |
Competing Products
20 competing products in Essential Hypertension